Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of eptinezumab for preventive treatment of chronic migraine
CTR20211849Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of eptinezumab in migraine, chronic migraine, sponsored by Lundbeck. Started Oct 2021; status: completed.
02
Drugs
eptinezumab
03
Conditions
migrainechronic migraine
Beyond the preview
Go deeper on CTR20211849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211849.